dc.contributor.advisor | Momtaz, Tanisha | |
dc.contributor.author | Afrin, Sadia | |
dc.date.accessioned | 2024-10-27T09:39:25Z | |
dc.date.available | 2024-10-27T09:39:25Z | |
dc.date.copyright | 2022 | |
dc.date.issued | 2022-02 | |
dc.identifier.other | ID 16346051 | |
dc.identifier.uri | http://hdl.handle.net/10361/24408 | |
dc.description | This thesis is submitted in partial fulfilment of the requirements for the degree of Bachelor of Pharmacy, 2022. | en_US |
dc.description | Catalogued from PDF version of thesis. | |
dc.description | Includes bibliographical references (pages 26-31). | |
dc.description.abstract | Traditional treatments and symptomatic care are still the only options for most patients as no therapeutic drug has been licensed for treating COVID-19 yet. Monoclonal antibodies generated from convalescent patients or humanized mice exposed to SARS-CoV-2 antigens were awarded emergency use authorization. An ongoing phase I, II, and III placebo-controlled trial is testing whether symptomatic adults can be treated safely and effectively. Casirivimab and imdevimab may have a therapeutic benefit in people who were seronegative when they received treatment. An IgG1 (Immunoglobulin G1) with an unaltered Fc region, Bamlanivimab was generated from the convalescent plasma of a COVID-19 patient. Patients with renal impairment, pregnancy, or breastfeeding status are not advised to alter their dosages. SARS-genomic CoV-2's organization is nearly identical to that of SARS-CoV, with the exception of a few genes for accessory proteins. | en_US |
dc.description.statementofresponsibility | Sadia Afrin | |
dc.format.extent | 31 pages | |
dc.language.iso | en | en_US |
dc.publisher | Brac University | en_US |
dc.rights | BRAC University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. | |
dc.subject | Casirivimab | en_US |
dc.subject | Imdevimab | en_US |
dc.subject | Bamlanivimab | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | Immunoglobulin G1 | en_US |
dc.subject | Placebo-controlled trial | en_US |
dc.subject.lcsh | Covid 19--Treatment. | |
dc.title | A review on role of anti-SARS-CoV-2 monoclonal antibodies in the treatment of COVID-19 | en_US |
dc.type | Thesis | en_US |
dc.contributor.department | Department of Pharmacy, BRAC University | |
dc.description.degree | B. Pharmacy | |